Brean Capital Initiates Coverage on Cytosorbents Corp (CTSO)
Stock analysts at Brean Capital initiated coverage on shares of Cytosorbents Corp (OTCMKTS:CTSO) in a research note issued on Tuesday. The brokerage set a “buy” rating on the stock.
Separately, Maxim Group reiterated a “buy” rating on shares of Cytosorbents Corp in a report on Wednesday, June 15th.
Shares of Cytosorbents Corp (OTCMKTS:CTSO) opened at 6.734 on Tuesday. The stock’s market cap is $171.29 million. The stock’s 50 day moving average is $5.59 and its 200-day moving average is $4.76. Cytosorbents Corp has a 12-month low of $3.11 and a 12-month high of $8.10.
Cytosorbents Corp (OTCMKTS:CTSO) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.03. The company had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $2.18 million. Equities analysts expect that Cytosorbents Corp will post ($0.39) EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Advisor Group Inc. purchased a new position in Cytosorbents Corp during the second quarter valued at approximately $1,372,000. Raymond James & Associates raised its position in Cytosorbents Corp by 318.6% in the second quarter. Raymond James & Associates now owns 324,603 shares of the company’s stock valued at $1,477,000 after buying an additional 247,052 shares during the period. Douglass Winthrop Advisors LLC purchased a new position in Cytosorbents Corp during the second quarter valued at approximately $321,000. BlackRock Fund Advisors raised its position in Cytosorbents Corp by 39.3% in the second quarter. BlackRock Fund Advisors now owns 53,915 shares of the company’s stock valued at $245,000 after buying an additional 15,203 shares during the period. Finally, Vanguard Group Inc. raised its position in Cytosorbents Corp by 1.0% in the second quarter. Vanguard Group Inc. now owns 537,707 shares of the company’s stock valued at $2,447,000 after buying an additional 5,446 shares during the period.
About Cytosorbents Corp
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Stock Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related stocks with our FREE daily email newsletter.